• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经内分泌肿瘤:流行病学、诊断与管理。

Neuroendocrine Neoplasms: Epidemiology, Diagnosis, and Management.

机构信息

Dunedin Hospital, 201 Great King Street, Dunedin 9016, New Zealand.

Department of Pathology, Dunedin School of Medicine, University of Otago, PO Box 56, Dunedin 9054, New Zealand.

出版信息

PET Clin. 2023 Apr;18(2):161-168. doi: 10.1016/j.cpet.2022.10.002. Epub 2023 Jan 25.

DOI:10.1016/j.cpet.2022.10.002
PMID:36707369
Abstract

Neuroendocrine tumors have variety of biological and clinical characteristics. The classification of neuroendocrine neoplasm has evolved, and the newest 2019 World Health Organization classification outlines a well-differentiated high-grade G3 subtype, recognizing its differences from the poorly differentiated neuroendocrine carcinoma. Ga-DOTAT PET has largely replaced somatostatin scintigraphy as the diagnostic workup choice for NENs. NETest, a multi-analyte liquid biopsy, is a promising recent development in the biochemical diagnosis. Management includes wait and watch approach, surgical resection, somatostatin analogs, Lu DOTATATE therapy, chemotherapy, radiotherapy or immunotherapy combinations. Further clinical trials are necessary for determining the appropriate sequencing.

摘要

神经内分泌肿瘤具有多种生物学和临床特征。神经内分泌肿瘤的分类已经发展,最新的 2019 年世界卫生组织分类概述了一种分化良好的高级别 G3 亚型,认识到它与分化不良的神经内分泌癌的不同。Ga-DOTAT PET 已在很大程度上取代了生长抑素闪烁显像,成为神经内分泌肿瘤的诊断选择。NETest 是一种多分析物液体活检,是生化诊断方面的一项有前途的最新进展。治疗包括等待观察、手术切除、生长抑素类似物、Lu DOTATATE 治疗、化疗、放疗或免疫治疗联合。需要进一步的临床试验来确定适当的治疗顺序。

相似文献

1
Neuroendocrine Neoplasms: Epidemiology, Diagnosis, and Management.神经内分泌肿瘤:流行病学、诊断与管理。
PET Clin. 2023 Apr;18(2):161-168. doi: 10.1016/j.cpet.2022.10.002. Epub 2023 Jan 25.
2
Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.奥曲肽受体显像在非(131)I 摄取的转移性分化型甲状腺癌中评估(177)Lu-DOTATATE 肽受体放射性核素治疗的可行性:适合肽受体放射性核素治疗的患者比例较低,且存在嗜铬粒蛋白 A 水平阳性神经内分泌分化的证据。
Clin Nucl Med. 2014 Jun;39(6):505-10. doi: 10.1097/RLU.0000000000000429.
3
Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms.评估治疗学在 3 级神经内分泌肿瘤中的作用。
J Nucl Med. 2019 Jul;60(7):882-891. doi: 10.2967/jnumed.118.217851. Epub 2019 Mar 8.
4
Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.68Ga-DOTATATE与18F-FDG PET/CT对神经内分泌肿瘤患者临床管理影响的比较
J Nucl Med. 2017 Jan;58(1):91-96. doi: 10.2967/jnumed.116.178095. Epub 2016 Aug 11.
5
Combined Quantification of F-FDG and Ga-DOTATATE PET/CT for Prognosis in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms.联合 F-FDG 和 Ga-DOTATATE PET/CT 对高级胃肠胰神经内分泌肿瘤进行预后评估。
Acad Radiol. 2022 Sep;29(9):1308-1316. doi: 10.1016/j.acra.2021.10.004. Epub 2021 Nov 24.
6
The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors.NETPET 评分:结合 FDG 和生长抑素受体显像优化治疗转移性高分化神经内分泌肿瘤。
Theranostics. 2017 Mar 1;7(5):1159-1163. doi: 10.7150/thno.19588. eCollection 2017.
7
Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective.68Ga-DOTATATE PET/CT对神经内分泌肿瘤管理的影响:转诊医生的观点
J Nucl Med. 2015 Jan;56(1):70-5. doi: 10.2967/jnumed.114.148247. Epub 2014 Dec 11.
8
Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.胃肠胰神经内分泌肿瘤患者中 68Ga-DOTANOC 与 68Ga-DOTATATE PET/CT 的比较。
J Nucl Med. 2013 Mar;54(3):364-72. doi: 10.2967/jnumed.112.111724. Epub 2013 Jan 7.
9
The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.68Ga-DOTATATE PET 在 111In-DTPA-octreotide 闪烁扫描阴性或不确定的神经内分泌肿瘤患者中的作用。
J Nucl Med. 2010 Jun;51(6):875-82. doi: 10.2967/jnumed.109.066134. Epub 2010 May 19.
10
The Correlation Between [Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs.胃泌素瘤神经内分泌肿瘤患者 [Ga]DOTATATE PET/CT 与细胞增殖的相关性。
Mol Imaging Biol. 2019 Oct;21(5):984-990. doi: 10.1007/s11307-019-01328-3.

引用本文的文献

1
Thyroid lesions of neuroendocrine origin? Thinking of a "polka-dotted" zebra! Case series from three Italian referral centers and review of the literature.神经内分泌起源的甲状腺病变?想想“带斑点的”斑马!来自三个意大利转诊中心的病例系列及文献综述。
J Neuroendocrinol. 2025 Sep;37(9):e70061. doi: 10.1111/jne.70061. Epub 2025 Jun 21.
2
Evaluating the prognostic significance of the pre-treatment neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios in Lu-DOTATATE PRRT treated patients with advanced metastatic neuroendocrine tumors.评估¹⁷⁷Lu-DOTATATE肽受体放射性核素治疗晚期转移性神经内分泌肿瘤患者中治疗前中性粒细胞与淋巴细胞比值和单核细胞与淋巴细胞比值的预后意义。
Endocrine. 2025 Mar 25. doi: 10.1007/s12020-025-04212-z.
3
Adverse Events of Radioligand Therapy in Patients with Progressive Neuroendocrine Neoplasms: The Biggest Eastern European Prospective Study.
放射性配体疗法治疗进展期神经内分泌肿瘤患者的不良事件:最大规模的东欧前瞻性研究
Cancers (Basel). 2024 Oct 17;16(20):3509. doi: 10.3390/cancers16203509.
4
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons.血脂异常、降脂药物与神经内分泌肿瘤:新的前景。
Endocrine. 2024 Aug;85(2):520-531. doi: 10.1007/s12020-024-03767-7. Epub 2024 Mar 20.
5
Analyses of sex-based clinicopathological differences among patients with gastrointestinal neuroendocrine neoplasms in Europe.欧洲胃肠道神经内分泌肿瘤患者基于性别的临床病理差异分析。
J Cancer Res Clin Oncol. 2023 Aug;149(10):7557-7563. doi: 10.1007/s00432-023-04711-4. Epub 2023 Mar 27.